Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 5Anus Neoplasms 2Sarcoma 1Rectal Neoplasms 1Pleural Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Mediastinal Neoplasms 1HIV Infections 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anal Canal Carcinoma 1

Interventions

Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Biopsy 2dehydroftorafur 1X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mitozytrex 1Mitomycin 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Colonoscopy 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anal Canal Carcinoma × Mitozytrex × 90 days × Clear all
NCT04166318 2026-05-05

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
252 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡